Table 3.
Main Cognition Outcome of the Included Studies (n=10)
| First Author (Year) | Measures | Assessment Timepoints | Reported Format / Time Point | Change Overtime | Correlates Tested |
|---|---|---|---|---|---|
| Cognition assessed more than once | |||||
| Alibhai (2009)18 | 2 items | pre-CT, 1m, 4m, 6m, 9m, 12m | mean score / all time points | Stable (no p-value) | remission status at 6m |
| Jouzier (2021)22 | MMSE (<26 CI) | at dx, 3rd cycle re-ICT, 6th cycle re-ICT, end-CCT | mean score / at dx P of CI at dx: 16% |
NS | gender, performance status, age, grade 3–4 toxicity during induction, time of induction, lomustine during induction and postinduction therapy |
| Klepin (2016)19 | 3MS (<77 CI) | pre-ICT, post-ICT | mean score / all time points P of CI: ≈> 20%→≈< 20% |
NS | - |
| Meyers (2005)20 | Digit Span, Digit Symbol, HVLT, COWA-verbal fluency, TMT, GPT | pre-CT, 1m | mean score / pre-CT P of impaired domains- attention: 7%→8% psychomotor speed: 8%→13% total recall: 44%→58% immediate recognition: 7%→25% delayed recall: 41%→58% verbal fluency: 17%→25% visual scanning: 28%→38% executive function: 29%→46% dexterity: 37%→54% |
P of impaired dexterity: S↑ P of other impaired domains: NS |
age, education, hemoglobin, fatigue, cytokines |
| Modzelewski (2011)21 | SPECT, ICARS, BI, TMT, 9HPT, DRS, Digit Span, GBVLT | at dx, pre-CCT, 2nd cycle CCT, during CCT, post-CCT, 6m | mean score / all time points P of normal test score: 100% |
SPECT at dx vs. pre-CCT vs. 2nd cycle CCT: NS R’t hand dexterity: S↑ during CCT–post-CCT L’t hand dexterity: S↓ 2nd cycle CCT–during CCT & S↑ post-CCT–6m attention: S↑ post-CCT–6m working memory: S↑ post-CCT–6m & S↑ at dx–pre-CCT verbal memory: S↑ at dx–6m global efficiency: S↑ at dx–6m |
- |
| Cognition assessed once | |||||
| Klepin (2011)26 | 3MS (<80 CI) | within 5d of initial hospitalization | mean score P of CI: 31.5% |
N/A | cytogenetics |
| Klepin (2013)23 | 3MS (<77 CI) | within 5d of initial hospitalization | median score P of CI: 28.8% |
N/A | - |
| Kotb (2019)27 | MOCA (<26 CI) | 6m–2y post-CT | mean score of each domain P of CI: 62.2% |
N/A | - |
| Molga (2020)24 | MMSE (<24 CI) | pre-treatment | N/A | N/A | - |
| Oliva (2011)25 | 2 items | at dx | IC group median score |
N/A | treatment |
Note: 2 items= cognitive function domain from the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), ≈ approximately, ↑ increased, ↓ decreased, S significant, L’t=left, R’t=right
Abbreviations: 3MS, Modified Mini-Mental State Examination; 9HPT, Nine Hole Peg Test; BI, Barthel Index; CCT, consolidation chemotherapy; CF, cognitive function; CI, cognitive impairment; COWA, Controlled Oral Word Association; CT, chemotherapy; d, days; DRS, Mattis Dementia Rating Scale; dx, diagnosis; GBVLT, Grober and Buschke Verbal Learning test; GPT, Grooved Pegboard Test; HVLT, Hopkins Verbal Learning Test; IC, intensive chemotherapy; ICARS, International Cooperative Ataxia Rating Scale; ICT, induction chemotherapy; m, months; MMSE, Mini-Mental State Exam; MOCA, Montreal Cognitive Assessment; N/A, not applicable; NS, non-specified; p, prevalence; SPECT, single-photon emission computerized tomography; TMT, Trial Making Test; y, years.